Home » Topics » Disease categories and therapies » Cancer

Cancer
RSS

Phase III Abraxane trial meets primary endpoint

Oct. 4, 2012

New B-raf inhibitors presented by Array BioPharma and Genentech

Oct. 4, 2012

ArQule and Daiichi Sankyo discontinue phase III MARQUEE trial

Oct. 3, 2012

SBIR grant supports Colby Pharmaceutical's work in prostate cancer

Oct. 3, 2012

GTx sells Fareston

Oct. 3, 2012

NuCana BioMed synthesizes new thymidylate synthase inhibitors

Oct. 3, 2012

Opaxio receives FDA orphan drug designation

Oct. 3, 2012

FDA approval sought for tivozanib

Oct. 2, 2012

Subcutaneous Velcade approved in Europe for multiple myeloma

Oct. 2, 2012

Results of lenvatinib trials in different kinds of cancer presented

Oct. 2, 2012

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 18, 2026.
GLP-1s need technologies for long-term use
BioWorld
For the long-term impact of GLP-1 therapies in obesity to be realized, they must be paired with data and digital tools. While the drugs are effective, challenges...
UTRN gene involved in arthrogryposis, study finds
BioWorld Science
Arthrogryposis multiplex congenita (AMC) is a group of disorders defined by two or more contractures in different body areas; while genes encoding sarcomeric...
HMNC raises $50M series B to prep depression drugs for phase III
BioWorld
HMNC Brain Health GmbH has raised $50 million in the first close of a series B, enabling the company to prepare the way for phase III trials of its two lead...
CFTX-2034 successfully shows promise for post-bariatric hypoglycemia in preclinical research
BioWorld Science
Researchers from Confo Therapeutics NV presented the preclinical characterization of CFTX-2034, a selective somatostatin receptor subtype 5 (SSTR5) agonist...